These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1425137)

  • 21. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans.
    Kang S; Brange J; Burch A; Vølund A; Owens DR
    Diabetes Care; 1991 Nov; 14(11):942-8. PubMed ID: 1797506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
    Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
    Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A shortened insulin with full in vitro potency.
    Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
    Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs.
    Plum A; Agerso H; Andersen L
    Drug Metab Dispos; 2000 Feb; 28(2):155-60. PubMed ID: 10640512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An insulin with the native sequence but virtually no activity.
    Wollmer A; Gilge G; Brandenburg D; Gattner HG
    Biol Chem Hoppe Seyler; 1994 Mar; 375(3):219-22. PubMed ID: 8011179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
    Nakagawa SH; Tager HS
    J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
    Ritzel R; Orskov C; Holst JJ; Nauck MA
    Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High resolution 1H-NMR studies of Des-(B26-B30)-insulin; assignment of resonances and properties of aromatic residues.
    Hua QX; Chen YJ; Wang CC; Wang DC; Roberts GC
    Biochim Biophys Acta; 1989 Feb; 994(2):114-20. PubMed ID: 2642711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues.
    Trajanoski Z; Wach P; Kotanko P; Ott A; Skraba F
    Biomed Tech (Berl); 1993 Sep; 38(9):224-31. PubMed ID: 8218870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions.
    Mirmira RG; Tager HS
    Biochemistry; 1991 Aug; 30(33):8222-9. PubMed ID: 1868095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of monomeric porcine DesB1-B2 despentapeptide (B26-B30) insulin at 1.65 A resolution.
    Diao JS; Wan ZL; Chang WR; Liang DC
    Acta Crystallogr D Biol Crystallogr; 1997 Sep; 53(Pt 5):507-12. PubMed ID: 15299880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose.
    Home PD; Pickup JC; Keen H; Alberti KG; Parsons JA; Binder C
    Metabolism; 1981 May; 30(5):439-42. PubMed ID: 6112654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.
    Howey DC; Bowsher RR; Brunelle RL; Woodworth JR
    Diabetes; 1994 Mar; 43(3):396-402. PubMed ID: 8314011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes.
    Kang S; Owens DR; Vora JP; Brange J
    Lancet; 1990 Feb; 335(8685):303-6. PubMed ID: 1967767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A highly potent insulin: des-(B26-B30)-[AspB10,TyrB25-NH2]insulin(human).
    Schwartz GP; Burke GT; Katsoyannis PG
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):458-61. PubMed ID: 2643113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action profiles of fast onset insulin analogues.
    Heinemann L; Starke AA; Heding L; Jensen I; Berger M
    Diabetologia; 1990 Jun; 33(6):384-6. PubMed ID: 2199281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action in dogs of slow-acting insulin analog O346.
    Ellmerer M; Hamilton-Wessler M; Kim SP; Dea MK; Kirkman E; Perianayagam A; Markussen J; Bergman RN
    J Clin Endocrinol Metab; 2003 May; 88(5):2256-62. PubMed ID: 12727983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-chain shortening of matrix-bound insulin with pepsin, II. Preparation and properties of camel des-pentapeptide (B26-30)- and des-PheB1-des-pentapeptide (B26-30)- insulin.
    Danho WO; Gattner HG; Nissen D; Zahn H
    Hoppe Seylers Z Physiol Chem; 1975 Sep; 356(9):1405-12. PubMed ID: 1100508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological properties and biological effectiveness of insulin analogues substituted at position B30.
    Neubauer HP; Obermeier R; Schnorr G
    Diabetologia; 1984 Jul; 27 Suppl():129-31. PubMed ID: 6383916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.